Demand
← Отчётные звонки
01
02
03
04 05 06
Тон
A1 A2 A3 A4
GILD
FY2025 Q4
Улучшается
Отчётный звонок Gilead Sciences, Inc.
Вывод Buzzberg
Yes2Go is expected to ramp steeply in 2026 toward blockbuster status.
Gilead reported solid FY2025 results, beating top-line guidance on strong HIV sales, with Yes2Go already hitting 90% payer coverage. Management gave a bullish 2026 outlook, including $29.6-30B total sales, an ~$800M Yes2Go ramp, and four potential launches. They also guided KITE cell therapy down ~10% due to competition and clinical trial headwinds. Yes2Go achieved 90% payer coverage in <6 months; $800M 2026 revenue guide implies ~5x from 2025.
Вывод Buzzberg Yes2Go is expected to ramp steeply in 2026 toward blockbuster status. Gilead reported solid FY2025 results, beating top-line guidance on strong HIV sales, with Yes2Go already hitting 90% payer coverage. Management gave a bullish 2026 outlook, including $29.6-30B total sales, an ~$800M Yes2Go ramp, and four potential launches. They also guided KITE cell therapy down ~10% due to competition and clinical trial headwinds. Yes2Go achieved 90% payer coverage in <6 months; $800M 2026 revenue guide implies ~5x from 2025. Читать полный анализСвернуть анализ
Gilead reported solid FY2025 results, beating top-line guidance on strong HIV sales, with Yes2Go already hitting 90% payer coverage. Management gave a bullish 2026 outlook, including $29.6-30B total sales, an ~$800M Yes2Go ramp, and four potential launches. They also guided KITE cell therapy down ~10% due to competition and clinical trial headwinds. Yes2Go achieved 90% payer coverage in <6 months; $800M 2026 revenue guide implies ~5x from 2025.
- HIV portfolio grew 6% in 2025, despite $900M Part D redesign headwind; 2026 growth guided to ~6% with 2% policy-related headwinds.
- KITE cell therapy expected to decline ~10% in 2026 due to in-class competition and clinical trial enrollment impacts.
- Livdelzi benefited from competitor withdrawal in US PBC, reaching >50% second-line market share.
CELL_THERAPY Выручка$1.8BФакт
HIV Выручка$20.8BФакт
LIVER Выручка$3.2BФакт
Выручка$7.924BФакт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Pipeline
Company targets four launches this year within a 10-launch pipeline through 2027.
HIV
BicLen once-daily combo could extend HIV switch leadership after H2 2026 launch.
Показать ещё 3 тезиса
Oncology
Trodelvy is the only ADC now recommended in first- and second-line mTNBC.
Cell Therapy
AnitoCell could launch H2 2026 with a best-in-disease CAR-T profile.
Strategy
No major LOEs until 2036 underpins a secure long-term growth runway.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| CELL_THERAPY Выручка | $1.8B | Факт |
| HIV Выручка | $20.8B | Факт |
| LIVER Выручка | $3.2B | Факт |
| Выручка | $7.924B | Факт |
| EPS | $1.86 | Факт |
| Валовая маржа | 79.51% | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $8.45–$8.85 | $8.65 | Начат |
| Выручка | FY2026 | $29.6B–$30B | $29.8B | Начат |
| ВыручкаYES2GO | FY2026 | $0.8B | $0.8B | Начат |
| ВыручкаCELL_THERAPY | FY2026 | -0.1% | -0.1% | Начат |
AI, капзатраты и спрос
Оценка менеджмента
Upbeat
Executives highlighted strong commercial execution, early beat-and-raise dynamics, and a dense launch calendar, framing 2026 as a period of strength and growth.
все упомянутые компании ниже: 9
Компаниис момента звонка
Конкуренты
Конкуренты
Dietmar Berger
Gilead is advancing Trodelvi in combination with Merck's Keytruda (pembrolizumab), positioning both companies in the frontline TNBC market.
Доказательства
“Trodelvi plus pembrolizumab in first-line PD-L1 positive metastatic TNBC in the second half of 2026.”
Конкуренты
Dietmar Berger
Gilead implicitly compares its own twice-yearly HIV candidate (GS3242) against Shionogi's, arguing Shionogi still needs a partner for a complete regimen.
Доказательства
“they cannot base once every six months treatment on one product only they also need a combination so we need to look at the overall development program that they have”
Конкуренты
Andrew Dickinson
Gilead's BD strategy may target assets in competitive spaces like oncology, which includes Pfizer's offerings.
Доказательства
“will continue to be active, and I'm confident that we'll add exciting new products over time”
Конкуренты
Joanna Mercier
Descovy's high market share in PrEP competes against generic Truvada (Roche has a stake via Genentech).
Доказательства
“record U.S. market share greater than 45%.”
Конкуренты
Daniel O'Day
Gilead's BD focus could target RNAi or other modalities where Alnylam is a leader, though no specific deal mentioned.
Доказательства
“we typically invest about $1 billion annually in smaller licensing deals, partnerships, and acquisitions.”
Конкуренты
Daniel O'Day
Gilead's oncology pipeline competes with BioNTech's in breast cancer and solid tumors.
Доказательства
“we have up to 10 ongoing and potential new launches through 2027”
Конкуренты
Cindy Peretti
Gilead expects KITE cell therapy sales to decline ~10% in 2026, in part due to more patients going into clinical trials for competitor CAR-Ts. — Competing clinical trial sites are diverting patients away from KITE's commercial products, a unique headwind that may persist until newer KITE products launch.
Доказательства
“our ability to serve the market at launch with 99% reliability and 16-day turnaround time, which again is very differentiated from the existing products on the market today.”
Конкуренты
Gilead expects KITE cell therapy sales to decline ~10% in 2026, in part due to more patients going into clinical trials for competitor CAR-Ts. — Competing clinical trial sites are diverting patients away from KITE's commercial products, a unique headwind that may persist until newer KITE products launch.
Joanna Mercier
Конкуренты
The withdrawal of Intercept's Ocaliva (obeticholic acid) from the US market is a direct tailwind for Gilead's Livdelzi in PBC.
Joanna MercierВнешние сигналы
Альфа цепочки поставок · 4с момента звонка
Gilead says Yes2Go has achieved 90% payer coverage in under six months, faster than expected, which lowers the friction to patient conversion.
Kite's anitocel launch will rely on a 16-day manufacturing turnaround vs competitors, a critical differentiator in a market where patients are sick.
Gilead expects KITE cell therapy sales to decline ~10% in 2026, in part due to more patients going into clinical trials for competitor CAR-Ts.
Gilead expects a 2% HIV sales headwind in 2026 due to the Medicaid Drug Pricing Agreement and Affordable Care Act changes, a concrete impact of recent policy changes.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 9. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.